Select Bibliography

 Search for any words:
Excel csv Word PDF RIS
  Filter by any of these (after searching):
      
Year
      
PubType
      
Endpoint
      
Analysis
      
Committee
      
Program
      
Meeting
      
Funding
                    Blood  

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 159 items

Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study Google Scholar
,  ,  ,  ... -    -  Blood   -  2010    
Abstract -  Secondary -  Primary -  Leuk Corr Sci -  C8525 ,  CALGB-10201 ,  CALGB-19808 ,  CALGB-20202 ,  CALGB-20502 ,  CALGB-8461 ,  CALGB-8923 ,  CALGB-9420 ,  CALGB-9621 ,  CALGB-9665 ,  CALGB-9720
Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (>= 60 years y ) and Younger (< 60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study Google Scholar
,  ,  ,  ... -    -  Blood   -  2009    
Abstract -  Secondary-not-in-original -  Primary -  Correl Sci NOS -  C8525 ,  CALGB-10201 ,  CALGB-19808 ,  CALGB-20202 ,  CALGB-20502 ,  CALGB-8461 ,  CALGB-8923 ,  CALGB-9420 ,  CALGB-9621 ,  CALGB-9665 ,  CALGB-9720
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study    QxMD    Google Scholar
,  ,  ... -    -  Blood   -  2008    
Manuscript -  Secondary -  Primary -  Leuk Corr Sci -  CALGB-19808 ,  CALGB-20502 ,  CALGB-8461 ,  CALGB-9621 ,  CALGB-9665
Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101 Google Scholar
,  ,  ,  ,  ... -    -  Blood   -  2009    
Abstract -  Primary -  Primary -  Leukemia -  CALGB-10101
Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study Google Scholar
,  ,  ,  ... -    -  Blood   -  2010    
Abstract -  Secondary -  Primary -  Leuk Corr Sci -  C8525 ,  C8641 ,  CALGB-10201 ,  CALGB-19808 ,  CALGB-20202 ,  CALGB-20502 ,  CALGB-8923 ,  CALGB-9420 ,  CALGB-9621 ,  CALGB-9665 ,  CALGB-9720
inv(16)/t(16;16) acute myeloid leukemia with non–type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations    QxMD    Google Scholar
,  ,  ... -    -  Blood   -  2013    
Manuscript -  Secondary -  Primary -  Leuk Corr Sci -  CALGB-8461 ,  CALGB-8525 ,  CALGB-8821 ,  CALGB-8923 ,  CALGB-9022 ,  CALGB-9120 ,  CALGB-9222 ,  CALGB-9621 ,  CALGB-9720 ,  CALGB-19808 ,  CALGB-10201 ,  CALGB-10502 ,  CALGB-10503 ,  CALGB-10603
Interfollicular CD10 Expression and Follicular PD1 Tumor-infiltrating lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab-based biologic therapy: An Alliance correlative science study (CALGB 50901, 50402, 50701, 50803, 50401) Google Scholar
,  ,  ,  ... -  ASH   -  Blood   -  2015    
Abstract -  Secondary-not-in-original -  Meta-Analysis -  Correl Sci NOS -  CALGB-50401 ,  CALGB-50402 ,  CALGB-50701 ,  CALGB-50803 ,  CALGB-50901
Toxicities and related outcomes of elderly patients (≥65 years) with hematologic malignancies in the contemporary era (Alliance A151611) Google Scholar
,  ,  ... -  ASH   -  Blood   -  2016    
Abstract -  Primary -  Primary -  Older Adult -  A151611 ,  CALGB-10101 ,  CALGB-10404 ,  CALGB-10501 ,  CALGB-19805 ,  CALGB-19901 ,  CALGB-50002 ,  CALGB-50103 ,  CALGB-50201 ,  CALGB-50401 ,  CALGB-50402 ,  CALGB-50501 ,  CALGB-50602 ,  CALGB-50701 ,  CALGB-50803
AFT Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) Google Scholar
,  ,  ... -  ASH   -  Blood   -  2018    
Abstract -  Primary -  Primary -  Myeloma -  AFT-29